Figure 2 | Scientific Reports

Figure 2

From: A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults

Figure 2

GMTs for SARS-CoV-2 neutralizing antibody: immunogenicity subset using two different methods: (a) cytopathic effect assay; (b) cell viability assay; and (c) GMTs for SARS-CoV-2 neutralizing antibody measured using the cytopathic effect assay in the S-268019-b group: immunogenicity subset in subgroups by age. CI, confidence interval; GMT, geometric mean titer; GMTR, geometric mean titer ratio; LLoQ, lower limit of quantification; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Wilcoxon rank-sum test was applied as a post hoc analysis for both methods because there was a certain level of proportion of neutralizing antibody titer below the LLoQ in the ChAdOx1 nCoV-19 group in the results of both methods.

Back to article page